According to new research, people who have had COVID enjoy strong immunity against the coronavirus for at least a year after they were initially infected. In analyzing antibodies present in the blood of COVID patients, Rockefeller scientists were able to track the evolution of these mutable molecules. They found that vaccination boosts the immunity these individuals naturally develop upon infection, so much that they are likely protected even from the emerging variants.
The 63 people in the study had COVID in the spring of last year. Data from their follow-ups show that, over time, antibodies produced by the immune system's memory B cells got better and better at neutralizing SARS-CoV-2, suggesting that these people were developing an improved, long lasting defense against the virus.
Moreover, the researchers found that these antibodies were further enhanced among 26 people in the group who had received at least one dose of the Moderna or Pfizer vaccine. This subset of people developed antibodies that are exceptionally resistant to the most concerning SARS-CoV-2 variants, such as those first isolated in the United Kingdom, South Africa, and New York City.
These potent antibodies are produced by groups of highly evolved memory B cells, which expand dramatically after a nudge by the vaccines, the team found.
The findings suggest that well-timed boosters with the current vaccines may provide additional protection in people who have never had the disease.
The study, carried out in the laboratories of Paul Bieniasz and Michel C. Nussenzweig, is available on bioRxiv ahead of publication in a peer-reviewed journal.
Vaccines charge up natural immunity against SARS-CoV-2 (2021, May 31)
retrieved 29 September 2022
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
Let us know if there is a problem with our content
E-mail the story
Vaccines charge up natural immunity against SARS-CoV-2